Cancer Research Targets Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Savinov, A. Y.
Right arrow Articles by Strongin, A. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Savinov, A. Y.
Right arrow Articles by Strongin, A. Y.
[Cancer Research 66, 2716-2724, March 1, 2006]
© 2006 American Association for Cancer Research

Cell, Tumor, and Stem Cell Biology

Matrix Metalloproteinase 26 Proteolysis of the NH2-Terminal Domain of the Estrogen Receptor ß Correlates with the Survival of Breast Cancer Patients

Alexei Y. Savinov1, Albert G. Remacle1, Vladislav S. Golubkov1, Maryla Krajewska1, Susan Kennedy2, Michael J. Duffy3, Dmitri V. Rozanov1, Stan Krajewski1 and Alex Y. Strongin1

1 The Burnham Institute, La Jolla, California; 2 Royal Victoria Eye and Ear Hospital, Dublin, Ireland; and 3 Department of Surgery, St. Vincents's University Hospital, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland

Requests for reprints: Alex Y. Strongin and Stan Krajewski, Cell Adhesion and Extracellular Matrix Biology, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037. Phone: 858-713-6271; Fax: 858-646-3192; E-mail: strongin{at}burnham.org and stan{at}burnham.org.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Estrogens have many cellular functions, including their interactions with estrogen receptors {alpha} and ß (ER{alpha} and ERß). Earlier, we determined that the estrogen-ER complex stimulates the transcriptional activity of the matrix metalloproteinase 26 (MMP-26) gene promoter. We then determined that ERß is susceptible to MMP-26 proteolysis whereas ER{alpha} is resistant to the protease. MMP-26 targets the NH2-terminal region of ERß coding for the divergent NH2-terminal A/B domain that is responsible for the ligand-independent transactivation function. As a result, MMP-26 proteolysis generates the COOH-terminal fragments of ERß. Immunohistochemical analysis of tissue microarrays derived from 121 cancer patients corroborated these data and revealed an inverse correlation between the ER{alpha}-dependent expression of MMP-26 and the levels of the intact ERß in breast carcinomas. MMP-26 is not expressed in normal mammary epithelium. The levels of MMP-26 are strongly up-regulated in ductal carcinoma in situ (DCIS). In the course of further disease progression through stages I to III, the expression of MMP-26 decreases. In contrast to many tumor-promoting MMPs, the expression of MMP-26 in DCIS correlated with a longer patient survival. Our data suggest the existence of an MMP-26–mediated intracellular pathway that targets ERß and that MMP-26, a novel and valuable cancer marker, contributes favorably to the survival of the ER{alpha}/ß–positive cohort of breast cancer patients. (Cancer Res 2006; 66(5): 2716-24)


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Human matrix metalloproteinases (MMP) are a family of 24 zinc enzymes that degrade the extracellular matrix and cell-surface molecules (1). The prodomain of all MMPs exhibits the sequence motif PRCG called the "cysteine-switch" (2). An unpaired Cys sulfhydryl group of the PRCG cysteine-switch binds the active site zinc. The Cys-Zn interactions are essential for maintaining the latency of MMP zymogens. There is, however, an exception from this general rule. An unconventional PH81CGVPD cysteine-switch distinguishes human MMP-26 from other members of the MMP superfamily (3–5). The presence of the His-81 in the immediate proximity of the Cys-82 residue, in addition to other atypical structural features, leads to the unorthodox, autolytic mechanisms of the MMP-26 zymogen activation and contributes to the unusual physiologic role of MMP-26 in cells and tissues (3, 6–13). In contrast with other MMPs, which are either secretory, soluble, or membrane-anchored enzymes, MMP-26 primarily accumulates in the intracellular milieu (4, 8, 10, 14).

The promoter of the MMP-26 gene includes the estrogen response element that binds estrogen receptors (ER; ref. 6). Signaling of estrogens, primarily 17ß-estradiol (E2), is transmitted by ERs. ERs are members of a nuclear receptor superfamily and are encoded by two distinct genes, ER{alpha} and ERß (15). Five ERß isoforms, which diverge at a common position within the predicted helix 10 of the ligand-binding domain, have been were identified and cloned (16). Our experimental work was done with the ERß1 isoform, which was termed ERß for the clarity of presentation in the text below.

ERs consist of five individual domains: the NH2-terminal A/B domain with a 16% sequence identity between the two ERs, the highly conserved central DNA-binding domain (96% sequence identity), the flexible hinge D domain (30% sequence identity), the ligand-binding domain (59% sequence identity), and the short COOH-terminal F domain (18% sequence identity). The A/B domain is responsible for the ligand-independent transactivation function (AF-1). The flexible hinge D domain contains a nuclear localization signal. The multifunctional ligand-binding domain domain, in addition to its role in ligand binding, is involved in dimerization and the ligand-dependent transactivation function (AF-2; ref. 17).

The E2-ER complex stimulates, via the binding of the estrogen response element motif, the transcriptional activity of the MMP-26 gene promoter in hormone-regulated neoplasms, including breast, ovarian, and endometrial carcinomas as well as the normal reproductive processes and menstrual cycle (6, 18–21). Using immunohistochemical analysis, we determined, however, that an inverse correlation, rather than a direct correlation, frequently occurs between the levels of MMP-26 and ER in biopsy samples from breast cancer patients. These findings prompted us to hypothesize that there is a regulatory loop in hormone-regulated malignancies and that this loop links E2-induced MMP-26 to the proteolysis of the ERs.

Our experiments, which are described in the current article, confirmed this hypothesis. We showed that the NH2-terminal portion of the A/B domain of ERß was sensitive to MMP-26 proteolysis in vitro and in cell-based assays. In the breast cancer patient cohort, the expression of MMP-26 correlated inversely with the residual levels of the intact ERß in the adenocarcinoma specimens. Elevated MMP-26 expression ductal carcinoma in situ (DCIS) was strongly associated with a longer overall survival in this patient cohort. Our results suggest that high levels of MMP-26 in the mammary epithelium at the early stages of its malignant transformation are a marker of a favorable prognosis. Conversely, the use of broad-range MMP inhibitors such as Marimastat, which is potent against MMP-26, is not favorable for breast cancer patients, a phenomenon observed in clinical trials (22).


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Chemicals and cells. Reagents were obtained from Sigma (St. Louis, MO) unless otherwise indicated. Human {alpha}1-antitrypsin (AAT) was obtained from Calbiochem (San Diego, CA). GM6001, a hydroxamate inhibitor, and rabbit polyclonal antibody AB1410 against the 1-12 amino acid NH2-terminal sequence region of ERß were obtained from Chemicon (Temecula, CA). The purified ER{alpha} and ERß were obtained from Invitrogen (Carlsbad, CA). Rabbit polyclonal antibody Ab-24 against the COOH-terminal part of ERß was obtained from LabVision (Fremont, CA). Mouse monoclonal antibody 14C8 directed against the 1-153 NH2-terminal sequence region of ERß was from GeneTex (San Antonio, TX). The rabbit polyclonal antibody against the COOH-terminal part of ER{alpha} and murine monoclonal antibody 1D5 against ER{alpha} were purchased from Santa Cruz (Santa Cruz, CA) and DakoCytomation (Carpinteria, CA), respectively. MMP-26 and the recombinant catalytic domain of membrane type 1 MMP (MT1-MMP) were expressed in E. coli and then purified from the inclusion bodies and refolded to restore their conformation and their catalytic activity (6, 23, 24). Rabbit polyclonal antibody, raised against the catalytic domain of MMP-26, was prepared and affinity purified as previously described (6). The total concentrations of MMP-26 and the catalytic domain of MT1-MMP were measured by absorption at 280 nm and calculated using a molar extinction coefficient of 39,000 and 57,000 L mol–1 cm–1, respectively. MT1-MMP and MMP-26 were each titrated with GM6001 to determine the precise concentration of catalytically active enzymes. Breast carcinoma MCF-7 cells were obtained from American Type Culture Collection (Manassas, VA). Endometrial carcinoma Ishikawa cells were a kind gift of Dr. Minoru Fukuda (The Burnham Institute, La Jolla, CA). Cells were routinely maintained in DMEM supplemented with 10% fetal bovine serum (FBS).

Cleavage assays. AAT, ER{alpha}, and ERß (500 ng each) were coincubated for 2 hours at 37°C with the indicated amounts of the proteases in 20 µL of 50 mmol/L HEPES buffer (pH 6.8), containing 200 mmol/L NaCl, 10 mmol/L CaCl2, 20 µmol/L ZnCl2, and 0.01% Brij-35. The reactions were stopped by adding 2% SDS and analyzed by SDS-PAGE. The digest fragments were identified by Coomassie staining or Western blotting.

Lentiviral expression of MMP-26. The full-length MMP-26 cDNA (10) was inserted into the SpeI-XhoI restriction sites of the pLenti6/V5-D-TOPO lentiviral vector under the control of the cytomegalovirus promoter. The lentiviral vector was amplified using a complete ViraPower Lentiviral Expression Kit in the 293FT producer cell line according to the instructions of the manufacturer (Invitrogen). The harvested viral supernatant was used to transfect MCF-7 cells. One week after transfection, the MMP-26 expression was determined by Western blotting of the total blasticidin-resistant MCF-7 cell pool. Subcloning of the cells was not used in these experiments.

Immunoblotting. Cells were lysed in either 50 mmol/L Tris-HCl buffer, (150 mmol/L NaCl, 1% IGEPAL, 0.25% sodium deoxycholate, 1 mmol/L sodium vanadate, 1 mmol/L sodium fluoride, and 1 mmol/L EDTA; pH 7.4) or 20 mmol/L Tris-HCl buffer (150 mmol/L NaCl, 0.1% SDS, 1% Triton X-100, 1% sodium deoxycholate, and 1% IGEPAL; pH 7.4). The lysis buffers were supplemented with a protease inhibitor cocktail for use with mammalian cells (Sigma) and with phenylmethylsulfonyl fluoride (1 mmol/L). Equal amounts of the total protein (~40 µg of total protein per sample) were analyzed by Western blotting with the MMP-26, ER{alpha}, and ERß antibodies followed by secondary species–specific immunoglobulin G (IgG) conjugated with horseradish peroxidase (HRP) and a TMB/M substrate (Chemicon).

Immunocytochemistry. Cells were subcultured in LabTek chamber slides. The attached cells were fixed twice for 3 minutes with Z-Fix (10% zinc-buffered formalin, pH 5.5; Anatech, Battle Creek, MI) and then blocked for 30 minutes with 2% bovine serum albumin and 1% normal goat serum. The slides were next incubated overnight at ambient temperature with the primary antibody diluted 1:2,000 to 1:6,000 in the DakoCytomation antibody diluent (DakoCytomation) supplemented with 1% goat normal serum. The colorimetric reaction was developed by incubating the slides with the HRP-conjugated goat anti-rabbit antibody and a 3,3'-diaminobenzidine substrate (0.25 mg/mL in PBS supplemented with 0.05% H2O2). Methyl green was used for counterstaining.

For immunofluorescence staining, cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, and incubated for 4 hours with the primary antibody diluted with PBS supplemented with 1% FBS and 0.1% sodium azide. The slides were then incubated for 2 hours with the secondary species–specific IgG conjugated with phycoerythrin. 4',6-Diamidino-2-phenylindole was used for nuclear staining. The slides were mounted in VectaShield antifading embedding medium (Vector, Burlingame, CA) and fluorescence-labeled cells were examined under a fluorescence microscope.

Patient specimens. Archival paraffin-embedded tissue specimens containing normal mammary epithelium (n = 16), in situ breast carcinomas (n = 23), and invasive breast tumors, represented by the ductal (n = 103), lobular (n = 15), and mucinous (n = 3) histologic subtypes, were obtained from St. Vincent's Hospital (Dublin, Ireland). These specimens represented the residual pathologic materials remaining after the diagnostic and hormone receptor determinations and were derived from women who presented in 2001 with the symptomatic stage I to III breast cancers. These samples were used for the preparation of tissue microarrays. Human breast surgical specimens were obtained under the Institutional Review Board approval of the Department of Surgery and Pathology, University College (Dublin, Ireland). In addition, 16 normal mammary epithelium specimens, excised from surgical margins, and 4 independent normal mammary gland tissue samples were included in the tissue microarrays. The breast cancer specimens have been fixed in 8% formalin and paraffin embedded according to routine procedures.

Tissue microarrays. To construct high-density breast cancer tissue microarrays, each containing 140 to 190 specimens, two to five 1-mm (diameter) cylindrical cores were taken from the representative areas of normal tissue (one core per patient) and of malignant tissues (two to three cores per patient) from archival paraffin blocks and arrayed into a new recipient paraffin block using a custom-built precision microarrayer (Beecher Instruments, Silver Spring, MD). Serial sections (4 µm) of the recipient block were applied to the Superfrost-Plus glass slides (Fisher, Pittsburgh, PA) coated with 3-aminopropyltriethoxysilane (25).

Immunohistochemistry. Following routine dewaxing, the tissue microarrays were stained with the polyclonal antibody against the recombinant catalytic domain of MMP-26 (6), the murine monoclonal antibody 1D5 to ER{alpha} (DakoCytomation), and the rabbit polyclonal antibodies AB1410 and Ab-24 against the ERß. Staining with the primary antibody was followed by a diaminobenzidine (DAB)-based detection method employing the Envision Plus HRP system (DakoCytomation) and an automated Dako immunostainer (26). For double-labeling experiments, tissue microarrays were stained first with the Envision Plus HRP system and a DAB substrate (brown color) and then with the second primary antibody followed by either alkaline phosphatase staining with the Vector 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium development or the avidin-biotin complex method-HRP system and SG chromagen (gray-black color). The slides were counterstained with Nuclear Red, dehydrated, and mounted with permanent mounting media. For all tissues examined, the immunostaining procedure was done in parallel using either preimmune serum or antiserum depleted by incubation with recombinant protein immunogen to verify specificity of the results. The immunostaining results were scored according to intensity as 0, negative; 1, weak; 2, moderate; and 3, strong. The scoring of immunostaining was calculated by multiplying the percentage of immunopositive cells (0-100) by the staining intensity score (0, 1, 2, and 3), yielding scores ranging from 0 to 300.

Statistical analysis. Data were analyzed using the STATISTICA software package (StatSoft, Tulsa, OK). The Student's t test was applied to characterize protein distribution in normal versus malignant tissues. Differences in the distribution of variables were tested using the Pearson's {chi}2 statistics for categorical variables and the ANOVA test for continuous variables. For the survival analysis, the immunostaining data were dichotomized at the median, comparing the clinical outcome for patients whose tumor immunoscores were above the median with those below the median. Breast cancer patient survival in relation to MMP-26 expression was analyzed using Kaplan-Meier curves in conjunction with the log-rank test.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
MMP-26 cleaves ERß in vitro. According to our earlier observations, the AAT serpin is a clinically relevant protein target of proteolysis by MMP-26 (6). Consistent with these data, the catalytic amounts of MMP-26 fully proteolyzed 61-kDa AAT (the enzyme/substrate molar ratio at a range of 1:15-1:150) in 2 hours in our studies and generated a 55-kDa NH2-terminal fragment and an ~6 kDa COOH-terminal fragment of AAT (Fig. 1A, top right; the 6-kDa fragment, which migrated to the bottom of the gels, was not shown). The potency of MT1-MMP in cleaving AAT was lower, albeit comparable, with that of MMP-26 (Fig. 1, top left). In turn, ERß was resistant to MT1-MMP but it was sensitive to proteolysis by the catalytic amounts of MMP-26 (the enzyme/substrate molar ratio at a range of 1:30-1:60). In contrast to ERß, ER{alpha} was not susceptible to MMP-26 (Fig. 1A, bottom). GM6001, tissue inhibitor of matrix metalloproteinase 1 (TIMP1), and TIMP2 fully inhibited the proteolysis of ERß by MMP-26 (not shown).


Figure 1
View larger version (45K):
[in this window]
[in a new window]
  		Figure 1. MMP-26 cleaves the NH2-terminal A/B domain of ERß. A, top, AAT is comparably sensitive to proteolysis by MT1-MMP and MMP-26. AAT was incubated with increasing amounts of MMP-26 and MT1-MMP to generate the 55-kDa cleavage fragment. Bottom, MMP-26 cleaves ERß (59 kDa), but not ER{alpha} (64 kDa), whereas ERß is resistant to the in vitro cleavage by MT1-MMP. The digest samples were separated by SDS-PAGE. The gels were stained with Coomassie to visualize the cleavage fragments. B, the MMP-26 cleavage fragment represents the COOH-terminal part of ERß. Following coincubation with MMP-26, the digest samples were analyzed by Western blotting with the antibodies 14C8 and AB1410 to the NH2-terminal part of ERß (right and middle, respectively) and the antibody Ab-24 to the COOH-terminal part of ERß (left). C, MMP-26 and the cleavage of ERß. MMP-26 is an estrogen-inducible gene (6) and the expression of cellular MMP-26 requires the presence of ER{alpha}/ERß in the cells. Estrogen, through either ER{alpha} or ERß or both, induces the expression of cellular MMP-26. MMP-26 cleaves the NH2-terminal sequence of ERß (59 kDa) and this cleavage generates the COOH-terminal fragments (51-54 kDa) of the receptor. The 1-148 NH2-terminal sequence represents the A/B transactivation domain of ERß. Shaded boxes, relative positions of the epitopes of the AB1410 (raised against the 1-12 NH2-terminal sequence of ERß), 14C8 (raised against the 1-150 NH2-terminal sequence of ERß), and Ab-24 (raised against the COOH-terminal part ERß) in the ERß sequence.

 
The cleavage by MMP-26 transformed the 59-kDa ERß into several digest fragments. The apparent molecular mass of the main digest fragments was in the range of 51 to 54 kDa but the shorter fragments were also observed in the digest samples. To identify the relative position of the cleavage fragments within the ERß polypeptide chain, we used the antibodies AB1410 and 14C8, and Ab-24, which recognized the NH2-terminal and COOH-terminal epitopes of ERß, respectively. The ERß samples were cleaved by increased amounts of MMP-26 and the digest samples were analyzed by Western blotting employing the AB1410, 14C8, and Ab-24 antibodies. As shown in Fig. 1B, the Ab-24 antibody against the COOH-terminal epitope recognized the intact ERß and the digest fragments whereas the Ab1410 and 14C8 antibodies against the NH2-terminal epitope reacted only with the intact ERß. These results indicate that MMP-26 proteolysis generated the stable cleavage fragments that represented the COOH-terminal portion of the ERß molecule. Because there were several closely overlapping digest fragments of ERß, we were unable to identify their NH2-terminal sequence by NH2-terminal microsequencing (not shown). The size difference in the apparent molecular weight between the intact ERß and the major ERß fragments suggested, however, that these stable, NH2-terminally truncated species are missing the first 40 to 60 NH2-terminal residues of the ERß A/B domain and, accordingly, we believe they are missing the functionality of the A/B domain which normally exhibits the ligand-independent AF-1 transactivation function of ERß. Figure 1C shows in a schematic manner the relative positions of the antibody epitopes, the A/B domain, and the MMP-26 cleavage site in the ERß polypeptide sequence.

MMP-26 cleaves cellular ERß. Although the available antibodies were generated to the specific sequence regions of the ERs or to the recombinant purified receptor proteins, because of the high degree of sequence homology between the ER{alpha} and ERß, we first showed the antibody specificity to the receptor subtypes. Using Western blotting of the purified ER{alpha} and ERß, we confirmed that the antibodies Ab-24, AB1410, and 14C8 to ERß did not cross-react with ER{alpha}. We also showed that the 1D5 antibody to ER{alpha} did not recognize ERß (not shown).

To confirm our in vitro cleavage data, we evaluated MMP-26 and ERß by immunoblotting in endometrial carcinoma Ishikawa cells and breast carcinoma MCF-7 cells. We specifically selected Ishikawa and MCF-7 cells for our studies because, according to our earlier reverse transcription-PCR (RT-PCR) results, these cells express substantial levels of the mRNA of MMP-26 (6, 10, 21). A purified MMP-26 control was included along with the Ishikawa extract in Western blot analysis. In agreement with the results of RT-PCR, total cellular extracts of Ishikawa cells (Fig. 2A, left) and MCF-7 cells (Fig. 2B, left) showed the presence of MMP-26. Consistent with the presence of MMP-26, the degradation products of ERß (51-54 kDa) along with the intact 59-kDa receptor were detected by immunoblotting with the ERß antibody Ab-24 in these cells. The molecular weight of the ERß degradation products observed in Ishikawa and MCF-7 cells was similar to that in the control MMP-26-cleaved samples of the purified recombinant ERß [Fig. 2A (middle) and B (right)]. The relative quantities of the ERß degradation products were significantly higher in Ishikawa cells when compared with MCF-7 cells.


Figure 2
View larger version (40K):
[in this window]
[in a new window]
  		Figure 2. The presence of MMP-26 correlates with the proteolysis of ERß in endometrial carcinoma Ishikawa cells and breast carcinoma MCF-7 cells. A, left, Western blotting of MMP-26 naturally expressed by Ishikawa cells and the purified MMP-26 control. Right, Western blotting of ERß expressed by Ishikawa and MCF-7 cells, intact ERß and ERß coincubated with MMP-26. B, left, Western blotting of MMP-26 from MCF-7 cells transfected with the control lentiviral vector (mock), the lentivirus bearing MMP-26 (MMP-26), and the purified MMP-26 control. Right, Western blotting of ERß from mock- and MMP-26-transfected MCF-7 cells, intact ERß, and ERß coincubated with MMP-26.

 
We next wanted to confirm the cleavage of the cellular ERß by MMP-26. For this purpose, we increased, by using cell transfection, the expression of MMP-26 in MCF-7 cells. Transfection of MCF-7 cells with a recombinant lentivirus bearing the full-length MMP-26 cDNA gene caused a noticeable increase in the MMP-26 levels (Fig. 2B, left). This increase correlated with an enhanced degradation of ERß in the transfected cells when compared with mock-transfected control (Fig. 2B, right). The NH2-terminal 6-kDa cleavage fragment of ERß was never detected in cell extracts, thus suggesting that this low molecular fragment was sensitive to proteolysis and that it was rapidly degraded by cellular proteinases.

In agreement with our earlier results as well as with the results of others (27–29), immunostaining confirmed the presence of both MMP-26 and ERß in Ishikawa cells (Fig. 3). ER{alpha} was not detected in Ishikawa cells. Consistent with the presence of the mRNA, as detected by RT-PCR, and the protein, as determined by Western blotting, immunofluorescence staining confirmed the expression of MMP-26 and ERß in MCF-7 cells (Fig. 3).


Figure 3
View larger version (59K):
[in this window]
[in a new window]
  		Figure 3. Immunostaining of Ishikawa and MCF-7 cells. Immunoreactivity was evident in Ishikawa cells stained with the MMP-26 antibody and the ERß antibody AB1410. There was no ER{alpha} immunoreactivity in Ishikawa cells. Immunofluorescence staining confirms the expression of MMP-26 and ERß (AB1410 antibody) in MCF-7 cells. The staining with the antibody control was negative.

 
Inverse correlations of MMP-26 with ERß in breast cancer cells. The redundancy of the MMPs as well as the low levels of MMP-26 expression in cells complicates the identification of ERß cleavage by MMP-26 in vivo. The available broad-spectrum hydroxamate inhibitors cannot specifically target and discriminate MMP-26 from the other structurally similar redundant MMPs. To overcome these experimental difficulties and to support our hypothesis that MMP-26 cleaves ERß in vivo, we employed an immunohistochemical approach to analyze the expression of MMP-26, ERß, and ER{alpha} in breast tissue specimens derived from stage I-III breast cancer patients and arranged in the tissue microarrays. Our manual immunoscoring method provided highly reliable data when compared with the digital scoring systems (30, 31).

Immunostaining determined that MMP-26 immunoreactivity was high both in in situ and invasive carcinomas when compared with the normal mammary epithelium (mean immunoscores of 71 ± 11.6, 43 ± 11.6, and 5 ± 2.8, respectively; P = 0.000003, ANOVA), with MMP-26 levels in in situ tumors considerably exceeding those in the other histologic categories (Fig. 4A). In invasive carcinomas, high MMP-26 immunoreactivity was associated with early clinical I-II stages compared with the late stage III (P = 0.01; Fig. 4B). These unbiased observations indicated that the up-regulation of MMP-26 is an early event in the pathogenesis of breast cancer.


Figure 4
View larger version (27K):
[in this window]
[in a new window]
  		Figure 4. Immunohistochemical analysis of MMP-26 and ERß in archival breast cancer biopsies. A, distribution of MMP-26 immunostaining in normal epithelium (NE), DCIS, and invasive carcinoma (invasive). Middle bar, mean; box and whiskers (bars), SE and SD, respectively. P = 0.000003, ANOVA. B, correlation of the MMP-26 expression with the clinical stage of breast cancer. Middle bar, mean for the early-stage (I-II) and the late-stage (III) breast carcinomas; box and whiskers (bars), SE and SD, respectively. P = 0.01, ANOVA. C, cumulative survival curves (Kaplan-Meier survival analysis) for MMP-26-positive DCIS. Low MMP-26 expression means immunoscore < 60; high MMP-26 expression indicates immunoscore > 60. The immunostaining data were dichotomized according to median immunoscore. P = 0.03, log-rank. D, inverse correlation of MMP-26 with ERß detected by immunohistochemistry. Scatter diagram of MMP-26 and ERß immunoscores shows the linear regression line. The negative correlation is measured by the correlation coefficient (r = –0.22). P = 0.01, ANOVA. E, cumulative survival curves (Kaplan-Meier survival analysis) for ERß expression in the ER{alpha}-positive breast cancer patient cohort. Low ERß expression means immunoscore < 80; high ERß expression indicates immunoscore > 80. P = 0.04, log-rank.

 
To correlate MMP-26 expression with the clinical outcome, the immunostaining data were dichotomized into the high versus the low protein levels using the median immunoscore as a cutoff. In the investigated cohort, patients with the enhanced expression of MMP-26 in in situ tumors enjoyed significantly longer disease-free and overall survival when compared with patients with the low levels of MMP-26 in in situ lesions (P = 0.03; Fig. 4C).

To determine possible associations between the expression of MMP-26 and the estrogen status of the tumors, the tissue microarrays also were stained for ER{alpha} (the antibody 1D5) and ERß (the antibody AB1410 to the NH2-terminal portion of the receptor). In agreement with our biochemical data which suggested that ERß is a cleavage target of MMP-26, the immunohistochemical analysis of the breast cancer tissue microarrays revealed an inverse correlation between the MMP-26 expression and the levels of immunoreactivity of the residual intact receptor: the high immunoreactivity of MMP-26 was accompanied by a concomitant loss of ERß in invasive adenocarcinomas (r = –0.22, P = 0.01; Fig. 4D). In agreement with other reports (32–34), our results showed that the presence of high levels of the intact ERß in the ER{alpha}-positive tumors favorably correlated with a patient's survival (Kaplan-Meier analyses; Fig. 4E). Consistent with volumes of other works, high levels of the ER{alpha} immunoreactivity correlated with a longer survival of the patients in the patient cohort available to our study (P = 0.01 for the overall survival and P = 0.04 for the disease-free survival; data not shown).

Figures 5 and 6 show the representative tissue microarrays immunostained for MMP-26, ER{alpha}, and ERß in invasive ductal carcinomas and DCIS, respectively. In agreement with the regulation of MMP-26 by E2, the presence of ER{alpha} is required for the induction of the MMP-26 expression in breast carcinoma cells. In the ER{alpha}/MMP-26–positive samples, the AB1410 immunoreactivity of ERß was low whereas the Ab-24 immunoreactivity of ERß was high, thus suggesting the predominant presence of the proteolyzed ERß (Figs. 5A-C and 6A-C). In turn, in the ER{alpha}-negative tumor specimens, the immunoreactivity of MMP-26 was minor and the Ab-24 immunoreactivity of ERß was similar to that of the AB1410 antibody, thus suggesting the predominant presence of the intact ERß (Figs. 5D-F and 6D-F).


Figure 5
View larger version (84K):
[in this window]
[in a new window]
  		Figure 5. Representative immunostaining of ER{alpha}, ERß, and MMP-26 in invasive ductal carcinomas. Tissue microarrays were stained (DAB, brown) with the antibody 1D5 to ER{alpha} (B and E) and with the antibody Ab-24 to the COOH-terminal portion of ERß (C and F). In double-labeling staining, tissue microarrays were stained with the antibody AB1410 to the NH2-terminal portions of ERß (DAB, brown; A and D) and with the antibody to MMP-26 (SR chromagen, gray-black). Tissue microarrays were counterstained with Nuclear Red (pink). A to F, the bottom portions (x60 magnification) show the respective enlarged images (x250 magnification).

 

Figure 6
View larger version (89K):
[in this window]
[in a new window]
  		Figure 6. Representative immunostaining of ER{alpha}, ERß, and MMP-26 in DCIS. Tissue microarrays were stained (DAB, brown) with the antibody 1D5 to ER{alpha} (B and E) and with the antibody Ab-24 to the COOH-terminal portion of ERß (C and F). In double-labeling staining, tissue microarrays were stained with the antibody AB1410 to the NH2-terminal portions of ERß (DAB, brown; A and D) and with the antibody to MMP-26 (SR chromagen, gray-black). Tissue microarrays were counterstained with Nuclear Red (pink). A to F, the bottom portions (x60 magnification) show the respective enlarged images (x250 magnification).

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
E2 and its {alpha} and ß receptors play a crucial role in the progression of hormone-dependent neoplasms, including breast cancer (15, 33, 34). The ERs have been targets for breast cancer treatment for years. ER{alpha} and ERß each play complex and distinct roles, which are not understood in detail, in regulating the cell response to E2. A recent comprehensive study of 305 breast cancer patients suggests that low levels of ERß predict resistance to Tamoxifen therapy in breast cancer (35). These data stimulated our interest in the intracellular proteolytic processes, which might regulate the concentrations and the functionality of ERß in breast carcinomas, and we focused our attention on MMP-26, a unique MMP, the expression of which is associated with carcinomas and is regulated by E2 (5, 8, 10, 21).

Consistent with the earlier structure-functional features and cellular localization of MMP-26, our current results suggest that MMP-26, naturally expressed by the cells, was predominantly associated with the intracellular milieu (6, 8, 10). According to our additional results as well the observations of other authors (3, 5, 36), the presence of the unorthodox PH81CGVPD cysteine-switch motif in the sequence of MMP-26 stimulates the autolytic mechanism of the protease activation. The promoter of the MMP-26 gene represents the 5'-GGTCACTCTTGCCC-3' estrogen response element motif (nucleotides –129/–117), having a characteristic 13-bp palindromic element consisting of two 5-bp arms separated by a 3-bp spacer (6). In agreement with the presence of the estrogen response element in the MMP-26 gene promoter, E2, via its interactions with the ERs, regulated the MMP-26 gene expression in Ishikawa cells. These results explain the association of the MMP-26 expression with hormone-regulated malignancies and MMP-26 cycling in the course of a menstrual period (6, 9, 19, 20, 37, 38).

Based on these observations, we asked ourselves if MMP-26 proteolysis targets the cellular ERs. In the current study, we determined that MMP-26 proteolysis generates the NH2-terminally truncated receptor species of ERß which lack the 40- to 60-amino-acid-long NH2-terminal fragment. In turn, ER{alpha} is resistant to MMP-26. Our data indicate that MMP-26 attacks the NH2-terminal region of ERß. This sequence region of ERß represents a divergent NH2-terminal A/B domain that is responsible for the ligand-independent transactivation AF-1 function of the receptor (39).

Consistent with our biochemical in vitro data, endometrial carcinoma Ishikawa cells, which coexpress MMP-26 with ERß, naturally exhibit the proteolyzed form of ERß. Following the transfection with the MMP-26 construct, the proteolyzed ERß species was generated in breast carcinoma MCF-7 cells, which naturally express ERß.

Having shown the proteolysis of ERß by MMP-26 in a cellular setting, we did an unbiased immunohistochemical analysis of the tissue microarrays derived from 121 breast cancer patients. Consistent with the estrogen-dependent induction of the MMP-26 expression, we detected the presence of the protease only in the ER{alpha}-positive specimens. The proteolytic mechanism of the ERß regulation by MMP-26 is consistent with our immunochemical data. These data indicated that the high levels of MMP-26 expression correlated with the presence of the NH2-terminally truncated species of ERß, which was undetectable with the antibody to the NH2 end of the receptor but which were readily detectable with the antibody to intact COOH-end portion of the receptor. In contrast, ER{alpha}-negative and, consequently, MMP-26-negative biopsy samples exhibited the intact ERß forms, which were identified with equal efficiency by the NH2-end and the COOH-end targeting antibodies.

Overall, our analyses confirmed that there was an inverse correlation between the levels of MMP-26 and the levels of the intact ERß in breast cancer biopsies. According to our observations, the expression of MMP-26 was insignificant in normal mammary epithelium. The expression of the protease was high in stage I to II invasive carcinomas, especially in DCIS, whereas in stage III carcinomas the MMP-26 levels decreased. Our data were consistent with the earlier results by Zhao et al. (40) who showed that the expression levels of both MMP-26 mRNA and protein were highest in human breast DCIS compared with other breast tissue samples. Our data are also consistent with the recent report (41) that stated that MMP-26 is expressed by laminin-5-positive keratinocytes in the migrating area during wound repair, in benign skin disorders characterized by inflammation and microdisruptions of basement membrane, and also in grade 1 and 2 squamous cell cancers. MMP-26, however, was not present in dedifferentiated grade 3 tumors. Based on these independent observations, we suspect that MMP-26 is up-regulated during the early stages of cancer and then, as the cancer progresses, the levels of the enzyme decrease. It seems that MMP-26 is a part of an inflammatory response and that its presence contributes to a favorable prognosis of the disease progression. In agreement with this suggestion, we identified an unexpected, but significant, direct correlation between the expression of MMP-26 in ductal carcinomas in situ and patient survival. To the best of our knowledge, MMP-26, in addition to MMP-8 (42), is the only species of MMP that showed antitumor properties. From these perspectives, MMP-26 (matrilysin-2) is very different from MMP-7 (matrilysin-1), a structurally similar enzyme that is directly involved in tumor progression (43, 44). We believe the lack of MMP-26 in DCIS could be a novel and independent marker of aggressive growth of ER{alpha}/ß-positive breast carcinomas.

Taken together, our data suggest the presence of an MMP-26-mediated intracellular regulatory pathway that targets ERß in hormone-regulated malignancies. We suggest that this pathway plays an important role in E2 signaling by regulating the levels and the functionality of cellular ERß. Our results warrant further studies because they add another level of complexity to understanding and precisely deciphering the potential effects and clinical outcomes of using MMP inhibitors and ER antagonists in breast cancer therapy.


   Acknowledgments
 
Grant support: NIH grants CA098818 (S. Krajewski) and CA83017, CA77470, and RR020843 (A.Y. Strongin).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Xianshu Huang and Hirad Hedayat for excellent assistance in the construction and immunostaining of tissue microarrays.


   Footnotes
 
Note: A.Y. Savinov and A.G. Remacle contributed equally to this work.

Received 10/ 5/05. Revised 12/12/05. Accepted 12/28/05.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161–74.[Medline]
  2. Nagase H, Woessner JF, Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491–4.[Free Full Text]
  3. Zhao YG, Xiao AZ, Newcomer RG, et al. Activation of pro-gelatinase B by endometase/matrilysin-2 promotes invasion of human prostate cancer cells. J Biol Chem 2003;278:15056–64.[Abstract/Free Full Text]
  4. Park HI, Turk BE, Gerkema FE, Cantley LC, Sang QX. Peptide substrate specificities and protein cleavage sites of human endometase/matrilysin-2/matrix metalloproteinase-26. J Biol Chem 2002;277:35168–75.[Abstract/Free Full Text]
  5. Marchenko ND, Marchenko GN, Strongin AY. Unconventional activation mechanisms of MMP-26, a human matrix metalloproteinase with a unique PHCGXXD cysteine-switch motif. J Biol Chem 2002;277:18967–72.[Abstract/Free Full Text]
  6. Li W, Savinov AY, Rozanov DV, et al. Matrix metalloproteinase-26 is associated with estrogen-dependent malignancies and targets {alpha}1-antitrypsin serpin. Cancer Res 2004;64:8657–65.[Abstract/Free Full Text]
  7. Yamamoto H, Vinitketkumnuen A, Adachi Y, et al. Association of matrilysin-2 (MMP-26) expression with tumor progression and activation of MMP-9 in esophageal squamous cell carcinoma. Carcinogenesis 2004;25:2353–60.[Abstract/Free Full Text]
  8. Marchenko ND, Marchenko GN, Weinreb RN, et al. ß-Catenin regulates the gene of MMP-26, a novel metalloproteinase expressed both in carcinomas and normal epithelial cells. Int J Biochem Cell Biol 2004;36:942–56.[CrossRef][Medline]
  9. Goffin F, Munaut C, Frankenne F, et al. Expression pattern of metalloproteinases and tissue inhibitors of matrix-metalloproteinases in cycling human endometrium. Biol Reprod 2003;69:976–84.[Abstract/Free Full Text]
  10. Marchenko GN, Ratnikov BI, Rozanov DV, Godzik A, Deryugina EI, Strongin AY. Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. Biochem J 2001;356:705–18.[CrossRef][Medline]
  11. Uria JA, Lopez-Otin C. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. Cancer Res 2000;60:4745–51.[Abstract/Free Full Text]
  12. de Coignac AB, Elson G, Delneste Y, et al. Cloning of MMP-26. A novel matrilysin-like proteinase. Eur J Biochem 2000;267:3323–9.[Medline]
  13. Park HI, Ni J, Gerkema FE, Liu D, Belozerov VE, Sang QX. Identification and characterization of human endometase (Matrix metalloproteinase-26) from endometrial tumor. J Biol Chem 2000;275:20540–4.[Abstract/Free Full Text]
  14. Isaka K, Nishi H, Nakai H, et al. Matrix metalloproteinase-26 is expressed in human endometrium but not in endometrial carcinoma. Cancer 2003;97:79–89.[CrossRef][Medline]
  15. Gustafsson JA. Estrogen receptor ß—a new dimension in estrogen mechanism of action. J Endocrinol 1999;163:379–83.[CrossRef][Medline]
  16. Tong D, Schuster E, Seifert M, Czerwenka K, Leodolte S, Zeillinger R. Expression of estrogen receptor ß isoforms in human breast cancer tissues and cell lines. Breast Cancer Res Treat 2002;71:249–55.[CrossRef][Medline]
  17. Pettersson K, Gustafsson JA. Role of estrogen receptor ß in estrogen action. Annu Rev Physiol 2001;63:165–92.[CrossRef][Medline]
  18. Chegini N, Rhoton-Vlasak A, Williams RS. Expression of matrix metalloproteinase-26 and tissue inhibitor of matrix metalloproteinase-3 and -4 in endometrium throughout the normal menstrual cycle and alteration in users of levonorgestrel implants who experience irregular uterine bleeding. Fertil Steril 2003;80:564–70.[CrossRef][Medline]
  19. Pilka R, Whatling C, Domanski H, Hansson S, Eriksson P, Casslen B. Epithelial expression of matrix metalloproteinase-26 is elevated at mid-cycle in the human endometrium. Mol Hum Reprod 2003;9:271–7.[Abstract/Free Full Text]
  20. Li Q, Wang H, Zhao Y, Lin H, Sang QA, Zhu C. Identification and specific expression of matrix metalloproteinase-26 in rhesus monkey endometrium during early pregnancy. Mol Hum Reprod 2002;8:934–40.[Abstract/Free Full Text]
  21. Marchenko GN, Marchenko ND, Leng J, Strongin AY. Promoter characterization of the novel human matrix metalloproteinase-26 gene: regulation by the T-cell factor-4 implies specific expression of the gene in cancer cells of epithelial origin. Biochem J 2002;363:253–62.[CrossRef][Medline]
  22. Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 2003;22:177–203.[CrossRef][Medline]
  23. Ratnikov B, Deryugina E, Leng J, Marchenko G, Dembrow D, Strongin A. Determination of matrix metalloproteinase activity using biotinylated gelatin. Anal Biochem 2000;286:149–55.[CrossRef][Medline]
  24. Rozanov DV, Strongin AY. Membrane type-1 matrix metalloproteinase functions as a proprotein self-convertase. Expression of the latent zymogen in Pichia pastoris, autolytic activation, and the peptide sequence of the cleavage forms. J Biol Chem 2003;278:8257–60.[Abstract/Free Full Text]
  25. Rentrop M, Knapp B, Winter H, Schweizer J. Aminoalkylsilane-treated glass slides as support for in situ hybridization of keratin cDNAs to frozen tissue sections under varying fixation and pretreatment conditions. Histochem J 1986;18:271–6.[CrossRef][Medline]
  26. Krajewski S, Krajewska M, Turner BC, et al. Prognostic significance of apoptosis regulators in breast cancer. Endocr Relat Cancer 1999;6:29–40.[Abstract]
  27. Mueller SO, Hall JM, Swope DL, Pedersen LC, Korach KS. Molecular determinants of the stereoselectivity of agonist activity of estrogen receptors (ER) {alpha} and ß. J Biol Chem 2003;278:12255–62.[Abstract/Free Full Text]
  28. Bramlett KS, Burris TP. Target specificity of selective estrogen receptor modulators within human endometrial cancer cells. J Steroid Biochem Mol Biol 2003;86:27–34.[CrossRef][Medline]
  29. Robertson JA, Farnell Y, Lindahl LS, Ing NH. Estradiol up-regulates estrogen receptor messenger ribonucleic acid in endometrial carcinoma (Ishikawa) cells by stabilizing the message. J Mol Endocrinol 2002;29:125–35.[Abstract]
  30. Cuezva JM, Krajewska M, de Heredia ML, et al. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res 2002;62:6674–81.[Abstract/Free Full Text]
  31. Price JH, Goodacre A, Hahn K, et al. Advances in molecular labeling, high throughput imaging and machine intelligence portend powerful functional cellular biochemistry tools. J Cell Biochem Suppl 2002;39:194–210.[Medline]
  32. Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, et al. Estrogen receptor ß (ERß) level but not its ERß cx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res 2004;10:5769–76.[Abstract/Free Full Text]
  33. Fuqua SA, Schiff R, Parra I, et al. Expression of wild-type estrogen receptor ß and variant isoforms in human breast cancer. Cancer Res 1999;59:5425–8.[Abstract/Free Full Text]
  34. Fuqua SA, Schiff R, Parra I, et al. Estrogen receptor ß protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res 2003;63:2434–9.[Abstract/Free Full Text]
  35. Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA. Low levels of estrogen receptor ß protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res 2004;10:7490–9.[Abstract/Free Full Text]
  36. Park HI, Jin Y, Hurst DR, et al. The intermediate S1' pocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling. J Biol Chem 2003;278:51646–53.[Abstract/Free Full Text]
  37. Pilka R, Kudela M, Hansson S, Casslen B. [MMP-26 expression in endometrial explants treated with estradiol and progesterone]. Ceska Gynekol 2004;69:467–71.[Medline]
  38. Pilka R, Kudela M, Hansson S, Casslen B. [Novel matrix metalloproteinases in cycling endometrium]. Ceska Gynekol 2004;69:262–6.[Medline]
  39. Huang J, Li X, Maguire CA, Hilf R, Bambara RA, Muyan M. Binding of estrogen receptor ß to estrogen response element in situ is independent of estradiol and impaired by its amino terminus. Mol Endocrinol 2005;19:2696–712.[Abstract/Free Full Text]
  40. Zhao YG, Xiao AZ, Park HI, et al. Endometase/matrilysin-2 in human breast ductal carcinoma in situ and its inhibition by tissue inhibitors of metalloproteinases-2 and -4: a putative role in the initiation of breast cancer invasion. Cancer Res 2004;64:590–8.[Abstract/Free Full Text]
  41. Ahokas K, Skoog T, Suomela S, et al. Matrilysin-2 (matrix metalloproteinase-26) is up-regulated in keratinocytes during wound repair and early skin carcinogenesis. J Invest Dermatol 2005;124:849–56.[CrossRef]
  42. Balbin M, Fueyo A, Tester AM, et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 2003;35:252–7.[CrossRef][Medline]
  43. Jiang WG, Davies G, Martin TA, et al. Targeting matrilysin and its impact on tumor growth in vivo: the potential implications in breast cancer therapy. Clin Cancer Res 2005;11:6012–9.[Abstract/Free Full Text]
  44. Shiomi T, Okada Y. MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev 2003;22:145–52.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
A. Gutierrez-Fernandez, A. Fueyo, A. R. Folgueras, C. Garabaya, C. J. Pennington, S. Pilgrim, D. R. Edwards, D. L. Holliday, J. L. Jones, P. N. Span, et al.
Matrix Metalloproteinase-8 Functions as a Metastasis Suppressor through Modulation of Tumor Cell Adhesion and Invasion
Cancer Res., April 15, 2008; 68(8): 2755 - 2763.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Hughes, O. Agbaje, R. L. Bowen, D. L. Holliday, J. A. Shaw, S. Duffy, and J. L. Jones
Matrix Metalloproteinase Single-Nucleotide Polymorphisms and Haplotypes Predict Breast Cancer Progression
Clin. Cancer Res., November 15, 2007; 13(22): 6673 - 6680.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Savinov, A. Y.
Right arrow Articles by Strongin, A. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Savinov, A. Y.
Right arrow Articles by Strongin, A. Y.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online